The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Aide to RFK Jr. says White House is pushing for global price parity on GLP-1 drugs for weight loss. Read more here.

The price of Wegovy, Novo Nordisk’s blockbuster weight-loss drug, is $1,349 a month in the U.S.; in Germany, it’s $328. The U.S. price for Keytruda, a cancer treatment, is $191,000 ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Denmark’s economic growth, which was driven by what economists described as an “exceptional surge” in pharmaceutical exports, ...

Weight loss drugs Ozempic and Wegovy would no longer be covered by California’s health insurance for low-income people under ...

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

A new research paper shows that, in some ways, U.S. prescription drug spending is not necessarily all that high.